This was a biomarker sub-analysis from a registered Australian pilot trial (ACTRN12623000345684) that randomized 24 women with fibromyalgia syndrome to oral 1:1 THC:CBD cannabis oil or placebo, with 22 completing 16 weeks of follow-up.

Plasma was drawn at five timepoints and analyzed by ultra-high-performance liquid chromatography mass spectrometry for three N-acylethanolamines: PEA, OEA, and SEA. Anandamide and 2-AG were both below the detection limit and could not be evaluated.

Mean plasma PEA, OEA, and SEA stayed stable across both groups and all timepoints. Repeated-measures analysis found no significant effect of time, treatment group, or their interaction, and effect sizes were minimal (partial eta squared of 0.06 or less).

A companion paper from this same trial reported clinically meaningful pain relief for many participants on the same cannabis oil, which makes the flat biomarker result more notable rather than less.

When a treatment appears to help symptoms but a plausible peripheral biomarker does not move, there are a few honest explanations: the true mechanism may be central rather than peripheral, peripheral NAE levels may not reflect local tissue or central nervous system endocannabinoid tone, or the pilot may simply be underpowered to detect a small peripheral change.

The authors themselves frame this as evidence that peripheral NAEs have limited utility as biomarkers for monitoring response to this specific oral 1:1 THC:CBD formulation in fibromyalgia, and that the relevant mechanism is more likely central than peripheral.

For now, there is no validated blood test that can confirm a fibromyalgia patient is responding to medicinal cannabis. Clinical monitoring still depends on structured symptom tracking, function, sleep, and patient-reported outcome measures rather than a peripheral lab value.

That is not a failure of cannabis therapy. It is a reminder that a negative biomarker study can still leave a positive clinical signal intact, and that the two questions, does the patient feel better and does a specific blood marker change, are not the same question.

Fibromyalgia research has increasingly explored endocannabinoid system dysfunction as part of the condition’s biology, and clinicians frequently want an objective way to track whether a therapy is working beyond patient self-report.

This trial is a useful, concrete test of one such approach, peripheral NAE measurement, and its negative result should redirect attention toward central mechanisms and toward validated patient-reported and functional outcome measures rather than a blood draw.

What I like about this paper is that it is honest about a null result instead of burying it. A companion analysis from the same trial found real pain relief, and this analysis found no change in three peripheral endocannabinoid-related compounds. Both things can be true at once, and pretending otherwise would be worse medicine.

In my own practice, I do not lean on blood endocannabinoid levels to decide whether a fibromyalgia patient is responding to cannabis therapy, and this trial is a good reason why: the biology that matters here may be happening centrally, not in a peripheral blood draw. I still track function, sleep, pain scores, and what the patient tells me, because right now that remains the most reliable signal we have.

A Four-Step Reading Frame